Results 71 to 80 of about 1,567 (130)

CEFTAROLINE AS THERAPY OF CHOICE IN SEVERE PEDIATRIC PNEUMONIA: EVALUATION OF USE IN A LARGE TERTIARY HOSPITAL IN RECIFE-PE

open access: yesBrazilian Journal of Infectious Diseases
Introduction/Objective: Community-acquired pneumonia remains among the main causes of hospitalization and infant morbidity and mortality. The increase in resistance of Streptococcus pneumoniae and Staphylococcus aureus, including methicillin-resistant ...
Moacir Batista Jucá   +6 more
doaj   +1 more source

Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain [PDF]

open access: yes, 2019
Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial ...
Charbonneau, C.   +31 more
core   +1 more source

Exploring the role of ceftaroline in the treatment of community-acquired pneumonia [PDF]

open access: yes, 2018
A critical appraisal and clinical application of File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA, FOCUS 1 investigators.
Meyer, Zachary
core   +1 more source

Clinico-Economic Effectiveness of Ceftaroline Fosamil for the Treatment of Hospitalised Patients with Pneumococcal Community-Acquired Pneumonia from a Societal Perspective [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия, 2015
Objective. Due to high activity against Streptococcus pneumoniae ceftaroline fosamil (CF) presents a good option for the treatment of adults with pneumococcal communityacquired pneumonia (PCAP) requiring parenteral antibacterial therapy.
Belkova Yu.А.   +2 more
doaj  

Panton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: evaluation from the CANVAS studies.

open access: yesPLoS ONE, 2012
The impact of Panton-Valentine leukocidin (PVL) on the severity of complicated skin and skin structure infections (cSSSI) caused by Staphylococcus aureus is controversial.
Amy Tong   +12 more
doaj   +1 more source

In vitro Activity of Ceftaroline Against Pathogens Collected Globally from the AWARE Surveillance Program, 2016

open access: yes, 2017
Background Ceftaroline, the active metabolite of ceftaroline fosamil, is a cephalosporin developed for treating infections caused by Staphylococcus aureus, including methicillin-resistant S.
Dan Sahm   +2 more
core   +1 more source

Addition of ceftaroline fosamil or vancomycin to PMMA: An in vitro comparison of biomechanical properties and anti-MRSA efficacy

open access: yesJournal of Orthopaedic Surgery, 2019
Background: Ceftaroline is a cephalosporin that is effective against methicillin-resistant Staphylococcus aureus (MRSA) infections. The objective of this study was to determine the feasibility of using ceftaroline-loaded Polymethyl methacrylate (PMMA) as
Amber Haseeb   +3 more
doaj   +1 more source

In Vitro Activity of Ceftaroline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

open access: yes, 2010
The in vitro activity of ceftaroline was compared with those of ceftriaxone, clindamycin, imipenem, metro-nidazole, moxifloxacin, tigecycline, and vancomycin against 514 clinical anaerobic isolates using Clinical and Laboratory Standards Institute (CLSI)
Laura A. Mcdermott   +2 more
core   +1 more source

Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an In Vivo Microdialysis Study. [PDF]

open access: yesAntimicrob Agents Chemother, 2021
Edlinger-Stanger M   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy